Musculoskeletal Network Highlights Osteoarthritis Pharmacotherapy Options

Sep 19, 2012, 09:51 ET from UBM Medica US

NORWALK, Conn., Sept. 19, 2012 /PRNewswire/ -- UBM Medica US today announced that Musculoskeletal Network, an online resource for unique and efficient techniques on the management of musculoskeletal disorders, now offers an overview of systemic pharmacotherapy and intra-articular treatments for knee osteoarthritis.

Systemic treatments have significant positive effects on biomarkers that may be associated with Osteoarthritis disease progression, say authors Vijay B. Vad, MD, Hospital for Special Surgery and Weill Cornell Medical College, and Stanley H. Dysart, MD, Pinnacle Orthopaedics & Sports Medicine Specialists. Key points include:

  • NSAIDs have been shown to be significantly superior to placebo or acetaminophen for decreasing pain and stiffness and improving function but often involve adverse events.
  • Injection of corticosteroids is effective for symptomatic treatment, but there is no evidence to support disease-modifying activity.
  • Intra-articular hyaluronic acid may have disease-modifying chondroprotective activity and positive effects on biomarkers associated with disease progression.
  • The goals of future therapies will include not only pain reduction and function improvement but also early detection and early intervention.

This is the second article in a 3-part osteoarthritis series on Musculoskeletal Network. Part 1 offered a rationale for early treatment. Part 2 provides an update on nutraceuticals and other nonpharmacological interventions.

About UBM Medica US
Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach—online, in print, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, online communities, drug databases, digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Websites include,,,,,, and UBM Medica US is part of UBM Connect – which provides marketing services across a number of communities, the largest of which are healthcare, medical device design and advanced manufacturing. UBM Connect also includes UBM Studios, the global leader in interactive digital environments. UBM Connect is a UBM plc company. For more information, visit

Media contact:
Jason J. Golden
Content Marketing Manager